Key Takeaways PP405 is designed to directly stimulate dormant follicular stem cells to re-enter the growth phase, positioning it as a regenerative, mechanism-driven alternative to therapies that primarily preserve or thicken existing hair. Dormant follicles in alopecic scalp may retain stem cells; targeting quiescence biology aims to convert inactive units into terminal hair–producing ...
PP405, or PP-405, is a drug acting as a mitochondrial pyruvate carrier (MPC) inhibitor which is under development for the treatment of alopecia (hair loss), specifically androgenic alopecia (male pattern hair loss). [1][3][2][4] It is used topically as a 0.05% concentration gel on the scalp once-daily. [1][2][5][6] PP405 is a possible first-in ...
PP405 activates dormant hair follicle stem cells, restoring the natural regenerative capacity of the follicle and activating new hair growth in previously bald areas.
Explore the science behind PP405 for hair loss. Understand early research, how it works, and what to expect from this investigational treatment.
PP405 is a hair loss solution that may help early-stage hair loss—but it’s not available today. Learn what PP405 is and how it compares to other solutions.
Learn what PP405 is, how it works for hair loss, clinical trial updates, expected release date, and how it compares to finasteride or minoxidil.
PP405 is a topical small molecule developed to reactivate dormant hair-follicle stem cells by targeting a metabolic switch inside the follicle. In mid-2025, Pelage Pharmaceuticals, the developer, announced positive Phase 2a results, showing that the product was well-tolerated and produced measurable hair-density improvements in a subgroup of ...
News: BREAKING NEWS: PP405 Phase 2a Results: A New Frontier in Hair ...